Next-Generation Imaging
Advertisement
The combination treatment of dual-PSMA targeting with mAb and SML is feasible, and a follow-up study is in progress.
PROPELLER: Assessing a Novel Imaging Agent in Patients With Intermediate-, High-Risk Prostate Cancer
64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose.
POSLUMA is a diagnostic imaging agent for the PET detection of PSMA-positive lesions in patients with prostate cancer.
A newly developed prognostic risk score had a good model fit for predicting OS in internal and external validation cohorts.
When testing interaction with the use of MDT, patients with positive PSMA PET not receiving MDT had a higher risk of CR.
Several physicians highlight the newest data on radiation for metastatic prostate cancer and its role moving forward.
Dr. Sternberg shares the therapeutic options for nmCRPC patients, how stage at diagnosis impacts these options, and more.
A study evaluated patients with mCRPC who received 177Lu-PSMA-617 to determine OS and PSA-PFS rates.
Researchers used determined if an increase in ACM risk existed when sRT was delivered above a prespecified PSA level.
Scott Tagawa, MD, MS, FACP, explains the distinct ways in which PSMA imaging compares to standard cross-sectional imaging.
David Nanus, MD, details the ways in which PSMA PET varies in guidelines and is used to stage localized prostate cancer.
A cohort analysis found that PSMA PET at baseline, before pRT, or before sRT may predict from pelvic radiotherapy.
Novel Radiomic-Based Diagnostic Tool Identifies Patients at High Risk for Prostate Cancer Recurrence
A new analysis demonstrates “excellent potential” for a radiomic-based diagnostic tool to identify PC recurrence risk.
Alex Pozdnyakov, MD, explains the current utility and potential application of PSMA PET imaging in prostate cancer.
Dr. Deek shares how PSMA imaging used in both the STOMP and ORIOLE trials.
Dr. Ulaner details the current application and capabilities of molecular imaging in prostate cancer.
Tomi Jun, MD, shares the clinical actionability and utilization of NGS for prostate cancer in a changing treatment landscape.
The Ga-PSMA-11 and Ga-P16-093 PSMA-PET tracers are useful tools for surgical guidance in prostate cancer.
iQuest is the first AI-powered platform of its kind to aid in the development of personalized prostate cancer care plans.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726